N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9896435B2 · kind B2 · utility
2Cited by
9References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2013 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | Jan 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.